Literature DB >> 7687300

Multiplicity of virus-encoded helper T-cell epitopes expressed on FBL-3 tumor cells.

M Iwashiro1, T Kondo, T Shimizu, H Yamagishi, K Takahashi, Y Matsubayashi, T Masuda, A Otaka, N Fujii, A Ishimoto.   

Abstract

To identify retroviral antigenic determinants recognized by CD4+ T helper cells during tumor rejection, we established four noncytolytic, helper-type, CD4+ T-cell clones by limiting dilution cultures of mixed lymphocyte-tumor cultures from mice immune to a Friend virus-induced tumor, FBL-3. Among these, three T helper cell clones were isolated from C57BL/6 mice and the fourth was isolated from a (BALB/c x C57BL/6)F1 mouse. All these clones proliferated in response to the immunizing FBL-3 tumor cells in a major histocompatibility complex class II-restricted manner. Each clone expressed a distinct T-cell receptor with a characteristic combination of alpha and beta chains. The localization of helper T-cell determinants on viral proteins was analyzed with recombinant vaccinia viruses expressing Friend murine leukemia virus (F-MuLV) gag or env genes or shorter fragments of the env gene. Epitopes recognized by these T-cell clones were mapped to at least two distinct portions in the env region of the F-MuLV genome. These epitopes were identified more precisely with synthetic peptides derived from the F-MuLV envelope protein sequence. One of these epitopes was common to Friend and Moloney MuLVs and was located in the N-terminal region of the gp70 glycoprotein at amino acids 122 to 141. The second epitope, which was recognized in the context of hybrid I-Eb/d major histocompatibility complex class II molecule, was located close to the C-terminal end of gp70 at amino acids 462 to 479. In addition, a possible third epitope was located in the N-terminal half of the gp70 sequence and differed from the first epitope in that it was not cross-reactive with the Moloney MuLV envelope protein.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7687300      PMCID: PMC237837     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  48 in total

1.  Adoptive chemoimmunotherapy of murine leukemia with helper T lymphocyte clones.

Authors:  M A Bookman; R Swerdlow; L A Matis
Journal:  J Immunol       Date:  1987-11-01       Impact factor: 5.422

2.  Prediction of immunodominant helper T cell antigenic sites from the primary sequence.

Authors:  H Margalit; J L Spouge; J L Cornette; K B Cease; C Delisi; J A Berzofsky
Journal:  J Immunol       Date:  1987-04-01       Impact factor: 5.422

Review 3.  The molecular genetics of the T-cell antigen receptor and T-cell antigen recognition.

Authors:  M Kronenberg; G Siu; L E Hood; N Shastri
Journal:  Annu Rev Immunol       Date:  1986       Impact factor: 28.527

4.  Retrovirus antigens recognized by cytolytic T lymphocytes activate tumor rejection in vivo.

Authors:  F Plata; P Langlade-Demoyen; J P Abastado; T Berbar; P Kourilsky
Journal:  Cell       Date:  1987-01-30       Impact factor: 41.582

5.  The specificity of H-2-restricted cytotoxic T lymphocytes directed to AKR/Gross leukemia virus-induced tumors. III. Coordinate alterations in viral gp70 antigen expression and restoration of CTL-susceptibility to insusceptible variant tumors.

Authors:  R Manjunath; R F Graziano; W R Green
Journal:  J Immunol       Date:  1986-03-15       Impact factor: 5.422

6.  Hemolytic anemia and erythroleukemia, two distinct pathogenic effects of Friend MuLV: mapping of the effects to different regions of the viral genome.

Authors:  M Sitbon; B Sola; L Evans; J Nishio; S F Hayes; K Nathanson; C F Garon; B Chesebro
Journal:  Cell       Date:  1986-12-26       Impact factor: 41.582

7.  T-lymphocyte priming and protection against Friend leukemia by vaccinia-retrovirus env gene recombinant.

Authors:  P L Earl; B Moss; R P Morrison; K Wehrly; J Nishio; B Chesebro
Journal:  Science       Date:  1986-11-07       Impact factor: 47.728

8.  Vaccinia virus expression vector: coexpression of beta-galactosidase provides visual screening of recombinant virus plaques.

Authors:  S Chakrabarti; K Brechling; B Moss
Journal:  Mol Cell Biol       Date:  1985-12       Impact factor: 4.272

9.  Antigenic specificity of the cytolytic T lymphocyte response to murine sarcoma virus-induced tumors. III. Characterization of cytolytic T lymphocyte clones specific for Moloney leukemia virus-associated cell surface antigens.

Authors:  A Weiss; K T Brunner; H R MacDonald; J C Cerottini
Journal:  J Exp Med       Date:  1980-11-01       Impact factor: 14.307

10.  Genetic control of T cell responsiveness to the Friend murine leukemia virus envelope antigen. Identification of class II loci of the H-2 as immune response genes.

Authors:  M Miyazawa; J Nishio; B Chesebro
Journal:  J Exp Med       Date:  1988-11-01       Impact factor: 14.307

View more
  33 in total

1.  Essential role for virus-neutralizing antibodies in sterilizing immunity against Friend retrovirus infection.

Authors:  Ronald J Messer; Ulf Dittmer; Karin E Peterson; Kim J Hasenkrug
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-05       Impact factor: 11.205

2.  Vaccination with an adenoviral vector that encodes and displays a retroviral antigen induces improved neutralizing antibody and CD4+ T-cell responses and confers enhanced protection.

Authors:  Wibke Bayer; Matthias Tenbusch; Ruth Lietz; Lena Johrden; Simone Schimmer; Klaus Uberla; Ulf Dittmer; Oliver Wildner
Journal:  J Virol       Date:  2009-12-09       Impact factor: 5.103

3.  Fine structure of a virus-encoded helper T-cell epitope expressed on FBL-3 tumor cells.

Authors:  T Shimizu; H Uenishi; Y Teramura; M Iwashiro; K Kuribayashi; H Tamamura; N Fujii; H Yamagishi
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

Review 4.  Immunity to retroviral infection: the Friend virus model.

Authors:  K J Hasenkrug; B Chesebro
Journal:  Proc Natl Acad Sci U S A       Date:  1997-07-22       Impact factor: 11.205

5.  Role of natural killer cells in resistance against friend retrovirus-induced leukemia.

Authors:  N Iwanami; A Niwa; Y Yasutomi; N Tabata; M Miyazawa
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

6.  Retroviral infection in vivo requires an immune escape virulence factor encrypted in the envelope protein of oncoretroviruses.

Authors:  Géraldine Schlecht-Louf; Martial Renard; Marianne Mangeney; Claire Letzelter; Aurélien Richaud; Bertrand Ducos; Isabelle Bouallaga; Thierry Heidmann
Journal:  Proc Natl Acad Sci U S A       Date:  2010-02-08       Impact factor: 11.205

7.  Identification of a gag-encoded cytotoxic T-lymphocyte epitope from FBL-3 leukemia shared by Friend, Moloney, and Rauscher murine leukemia virus-induced tumors.

Authors:  W Chen; H Qin; B Chesebro; M A Cheever
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

8.  A single retroviral gag precursor signal peptide recognized by FBL-3 tumor-specific cytotoxic T lymphocytes.

Authors:  T Kondo; H Uenishi; T Shimizu; T Hirama; M Iwashiro; K Kuribayashi; H Tamamura; N Fujii; R Fujisawa; M Miyazawa
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

9.  Passive immunotherapy for retroviral disease: influence of major histocompatibility complex type and T-cell responsiveness.

Authors:  K J Hasenkrug; D M Brooks; B Chesebro
Journal:  Proc Natl Acad Sci U S A       Date:  1995-11-07       Impact factor: 11.205

10.  Contrasting effects from a single major histocompatibility complex class II molecule (H-2E) in recovery from Friend virus leukemia.

Authors:  L L Perry; M Miyazawa; K Hasenkrug; K Wehrly; C S David; B Chesebro
Journal:  J Virol       Date:  1994-08       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.